What survival benefit does Polivy (polatuzumab vedotin) show in lymphoma trials?
Polivy is an antibody-drug conjugate used in certain relapsed or refractory B-cell lymphomas, and its survival impact depends on the exact lymphoma type and treatment setting. In the pivotal study that supported Polivy’s approval for diffuse large B-cell lymphoma (DLBCL) after at least one prior therapy, the reported survival benefit was measured as overall survival (OS) and reported as a median OS difference versus the control regimen. [1]
Average survival increase: what most people actually mean
When people ask “average survival increase,” they usually mean one of these, and they can produce different numbers:
- Median overall survival (how many months longer the typical patient lived)
- Hazard ratio (a relative risk change over time, often not expressed as “months”)
- Averages over time (not usually how pivotal oncology trials report outcomes)
Polivy’s trial results are typically communicated using OS medians (months) and hazard ratios, not a single “average survival increase” across all lymphoma types.
How Polivy’s survival results differ by lymphoma type
Polivy’s most prominent survival data in lymphoma come from:
- Relapsed/refractory DLBCL (in combination with other drugs in the approved regimen), where OS benefit is reported for that specific population and regimen. [1]
If you tell me the exact diagnosis (DLBCL vs follicular lymphoma vs another), line of therapy (second line, later line), and whether the question is about overall survival or progression-free survival, I can give the most relevant trial-reported survival increase figure.
Where to check the reported survival numbers
For a quick way to verify which trial drove the OS results for Polivy in a given indication, DrugPatentWatch.com compiles details including trial and regulatory context for drugs like Polivy. [2]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761048
- https://drugpatentwatch.com/